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CINDY L. BRISTOW. Role of Serum Amyloid P Component in Immune 
Clearance. 
(Under the direction of Dr. Robert J. Boackle.) 
In order to clarify the mechanism of interaction of serum amyloid P 
component (SAP) with complement, the interaction of SAP with Clq was 
studied. It is known that SAP binds Sepharose 4B in the presence of 
calcium. 125I-Clq was retained on the Sepharose when purified 125I-Clq 
was incubated with SAP prior to affinity chromatography on Sepharose. 
In the absence of SAP, the 125I-Clq was not retained. To further examine 
the interaction of SAP with Clq, SAP was incubated at va~ing ratios 
with Clq. These mixtures were examined via crossed immunoelectro-
immunoelectrophoresis against goat anti-SAP. A change in the 
electrophoretic behavior of SAP was observed in the presence of Clq. It 
was found that SAP interacted with the collagen-like stem of Clq. In 
these studies, 1 25r-SAP was incubated with pepsin digests of Clq in a 
microtitre solid-phase binding assay. In addition, a microtltre 
solid-phase binding assay was utilized in order to investigate the 
possible binding of SAP with IgG. Interestingly, human IgG and Fabr , 
but not Fc~, were found to bind 125I_SAP~ Furthermore, 125I-SAP-IgG 
complexes bound to immobilized Clq, whereas 125I-SAP-Clq complexes 
,demonstrated significantly less binding to IgG. 
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The ability of SAP to activate complement as detected by C3 
conversion was studied. It was found that SAP activated complement to a 
limited extent in normal human serum but caused extensive C3 conversion 
when serum from an individual with decreased levels of Cl inhibitor was 
used. Furthermore, the activation of the complement pathway by SAP in 
the latter serum was reversed by the addition of exogenous Cl inhibitor, 
indicating that SAP has the ability to playa role in the regulation of 
complement via the classical pathway. 
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CHAPTER 1 
BIOCHEMICAL AND BIOLOGICAL CHARACTERISTICS OF 
HUMAN SERUM AMYLOID P COMPONENT AND Clq 
2 
I. Biochemical and biological characteristics of human SAP 
A. Biochemical characteristics of SAP. 
1. Amyloid P component in amyloid deposits. 
Amyloidosis is an epiphenomenon which occurs as a result of 
prolonged acute phase responses in cases of chronic inflammation and 
prolonged stimulation of the reticuloendothelial system. Character--. 
istic of this enigmatic disease is the deposition of proteinacious 
fibrils at various organ sites depending on the nature of the primary 
disease. The etiology of amyloidosis is not known, but the composition 
of amyloid deposits has been established. The disease has been 
classified as "primary" when the amyloid fibrils are composed of light 
chains of immunoglobulin (1) and "secondary" when the fibrils are 
composed of amyloid A protein (2), an acute phase reactant of unknown 
function. Other forms of amyloidosis have been reported where the 
fibrillar component is neither amyloid A component nor immunoglobulin 
light chain. For example, pre-albumin (3) and{32microglobulin (4) have 
been identified to be the fibrillar component in isolated cases. In 
cases of amyloidosis; regardless of the nature of the fibril component, 
there is another associated protein, amyloid P component (AP) which 
does not form fibrils, but is found bound to the fibrils in amyloid 
deposits (2). 
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2. Localization of amyloid P component in tissue. 
Amyloid P was first detected in amyloid deposits. Later it was 
demonstrated to be a normal plasma constituent of every vertebrate 
species studied (5). In 1978, SAP was discovered in basement membrane 
and was mistakenly thought to be a form of type IV collagen (6). As 
was later discovered, this mis-named, mis-identified, and poorly 
understood glycoprotein is a normal matrix constituent in glomerular 
basement membrane (7). Amyloid P has been reported to be covalently 
associated with collagen and/or other matrix proteins in basement 
membrane (8). Furthermore, by direct immunofluorescent staining of 
normal human tissues with anti-SAP, it was demonstrated that SAP is --
associated with elastic fibers in the connective tissue of kidney, 
skin, lung, gut, heart, and blood vessels (8). There is close 
morphological association in vivo between amyloid fibrils and 
microfibrils of elastic fibers. Because most amyloid deposits and 
inflammatory responses involve basement membranes, the importance of 
the localization of SAP in basement membrane is obvious. 
3. Amyloid P component in serum. 
Serum amyloid P component (SAP) is a 9.5 S~1-g1ycoprotein (5) 
found in plasma as well as in basement membrane (7,8). This 250,000 
molecular weight glycoprotein has been shown to be antigenically 
identical to the amyloid P component found in amyloid deposits (9). 
SAP is made up of 10 identical 23,500 molecular weight subunits 
noo-covalently linked to form two face-to-face pentagonal structures 
(10). The similarity in structure and amino acid sequence between 
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SAP, C-reactive protein (CRP) , and hamster female protein (HFP) has led 
to the classification of these pentameric proteins as pentraxins 
(10,11). In humans, SAP, unlike CRP, is not an acute phase reactant 
(12). In contrast, CRP is not an acute phase reactant in mouse whereas 
SAP is an acute phase reactant (13). B.y some unnatural twist of fate, 
HFP, the hamster counterpart of human SAP and CRP,is an acute phase 
reactant in the male but a normal plasma constituent is the female 
(13). This is an interesting characteristic of HFP because it 
indicates that the activities of SAP and CRP may be hormonally 
controlled in human as well. 
SAP has been found in all vertebrate species studied and has never 
been found to be deficient in any individual (13). Furthermore, the 
N-terminal amino acid sequence of SAP in plaice, a teleost fish, has 
50% homology with human SAP (13). When the amino acid sequences of 
human SAP and CRP are compared, they are almost 70% homologous (14). 
Very recently the gene coding for SAP has been localized to chromosome 
1 indicating that the SAP gene is probably linked to the gene for CRP 
(15). The evolutionary conservation of SAP indicates it mediates an 
important function. In man, SAP has been found to be present in 
concentrations of 10-100 ug/ml with an average of 40 ug/ml (13). This 
level is consistent throughout life and is found to increase only 
slightly in chronic inflammatory disease. 
The carbohydrate composition of SAP is 11.2% consisting of 5.6% 
neutral sugars, 3.0% glucosamine, and 2.6% sialic acid (16). The 
presence of microheterogeneity in SAP has been attributed to amino acid 
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residues as opposed to differences in glycosylation (14), although the 
genetic basis for this microheterogeneity has yet to be established. 
B. The biological function of SAP. 
1. The interaction of SAP with the complement system. 
a. The interaction of SAP with the first component of complement. 
Although SAP has been extensively characterized biochemically, 
little information is available to elucidate its biological function. 
Assimeh and painter (16) reported they had identified a fourth 
subcomponent of the first component of complement, which they 
designated CIt. The Clt molecule was shown to co-purify with Cl when 
serum vas passed through a column containing IgG coupled to Sepharose 
(16). Later, the Clt molecule was found to actually be SAP (17). It 
was shown that SAP had affinity for Sepharose itself, and therefore, 
it was suspected that SAP was not actually a subcomponent of Cl (18). 
Subsequently, Cooper and Ziccardi (19) showed in a variety of assays 
that SAP neither functionally nor physically interacted with C1. 
b. The interaction of SAP with fixed complement. 
Although the hypothesis that SAP could interact with the Cl 
molecule had been disproved, evidence indicated that SAP might, in 
fact, interact with the complement system. It was shown in 1980 that 
SAP could agglutinate complement-coated, antibody-sensitized sheep 
erythrocytes in a calcium dependent manner (20). By using sera 
':defieient for various complement componel!:tJ'r£ ff?u.n' tI:ma.mcrg. tlie.: antii,1)odtv-
sensitized erythrocytes, it was concluded. i:U:m.tii. ~) ~ iJniienar.rtJ.ilng( ~'t1fu 
. on the complement-coated erythrocytes witb., ~tt-·!r.j1':D1fl)ill ,mdit!it :iJntiera~tla~ 
irreversibly with C3b't it was shown that 1i&''eS~ ~]$J wel1e: !,!Q'i ]Wlg~!r~ 
agglutinated by SAP (21). It -was suggesit~d.1 itftertt. ~) mllig;li1J inrn.e~a1'l1t 
with C3bi. Later these authors showed t~~l 'Wl!l$ ;:nm;- ~3~ <0.11' 
interacting with c4 on these erythrocytes~ 
c. The interaction of SAP with C4-b~~~ ~~~~~ ~; 
fibronectin. 
fibronect in were removed from serum wh6Jn ~. W1A.1$ JPla..aadl iift~u~~. (1; 
eluted with EDTA from the SAP-Sepharos~ i"Will11mt[: atni~ ~r.~~ anaiLy,z~dJ by;' 
the majority of the protein eluted in llidis.~ wal}f.,' 
gradient PAGE gel showed a deep-stainilt~~ 1:lmrnll at-n~ a!Y:l.nQlIt:i:ma;tEf11J~ "YlJtette' 
Clq would have migrated, although this p€rillntl was:', nero Jtt;sc.u.BJ~dt. 
Trace proteins in the eluate identifiet ilrnnnmarattemnJ'cai)Jj}..c Yfff!J&' ]$\1i,.,; 
IgG, IgA, C3, Clq, CIs, and SAP itself., ry]lnc at.g:t&v::al:ant. c'O!l(nmttt?~±L1.lc];Tirat 
of proteins were also recovered in the rl\].ni-$1(8 J 1l.E!a:rrii!1fg·' &epfiarrofHf;'" 
Although the non-SAP bearing Sepharose c1llillu.mn3 w;a;s~; mft.anit 'tio.; bff~ a·:. 
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adhered to the Sepharose beads at the physiologic concentration of 
calcium available thereby setting up a calcium-mediated, SAP-coupled 
Sepharose column. Were SAP to interact with complement directly or 
indirectly, it might have caused deposition of native or activated 
fragments of complement. In this case, some complement components 
would have become bound to the SAP complexes indirectly, thus leading 
to mistaken identification of ligands for the SAP molecule. Although 
purified fibronectin was shown to adhere to the SAP-Sepharose column, 
purified C4bp was not similarly tested. Therefore, it is still 
unclear whether C4bp directly interacts with SAP. The fact that 
purified fibronectin interacts with SAP is interesting because these 
two proteins are the only normal plasma constituents also found in 
'connective tissue. 
d. The activation of C3b receptors on macrophage membranes by 
SAP. 
Both fibronectin and SAP have been shown to stimulate macrophage 
uptake of sheep erythrocytes coated with C3b or C3bi (24) Although 
monocytes were unable to become activated to phagocytize C3b- or C3bi-
coated sheep erythrocytes alone, the presence of SAP or fibronectin 
promoted phagocytosis through activation of the C3 receptors of the 
macrophage (25). These authors suggested that SAP and fibronectin may 
also potentiate phagocytosis of C3-coated pathogens in vivo. 
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2. The interaction of SAP with the coagulation system. 
a. Inhibition of fibrin polymerization by SAP. 
As early as 1977 there was a report that amyloid P component 
interacted with heparin (25). In this abstract, it was reported that 
SAP inhibited the ability of heparin to block clot formation. In 1980, 
however, another group claimed that SAP potentiated heparin's 
anti-coagulant activity (26). In 1983, it was shown that SAP and 
heparin were both required and synergistic in preventing polymerization 
of the fibrin monomer by inhibition of fibrinopeptide A (FPA) release 
(27). It was further shown that SAP and heparin were synergistic in a 
system of purified components containing fibrinogen, thrombin, 
antithrombin III, SAP, and heparin, and that SAP became incorporated 
into the forming fibrin clot. 
The interaction of SAP and heparin is very interesting considering 
the fact that heparin potentiates several serine protease inhibitors 
such as C1 inhibitor (28), Factor H (29), and antithrombin III (30) 
which are involved in the regulation of both the coagulation and 
complement cascades. For this and other reasons, it has been suggested 
that SAP may be a regulatory protein in the coagulation and complement 
systems. 
b. The interaction of SAP with platelets. 
It has been demonstrated that heat-aggregated CRP activates 
platelets (31). Activation was measured as aggregation, secretion, and 
generation of thromboxane by platelets. In subsequent work, it was 
shown that SAP had the ability to inhibit platelet activation mediated 
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by heat-aggregated CRP, but not activation mediated by heat-aggregated 
IgG, acid-soluble collagen, DNA, ADP, or thrombin (32). However, since 
there is no in vivo counterpart of heat-aggregated CRP, these results 
are difficult to interpret. 
3. Effects of SAP on human lymphocytes. 
It has recently been reported that SAP has an inhibitory effect on 
T cell function as measured by lymphocyte proliferation induced by 
CoDA, PHA, and soluble protein A (33). In addition, SAP minimally 
enhanced the ability o~ T cells to form E-rosettes. The significance 
of the interaction of SAP with T cells in vivo is unknown. 
4. The lectin-like qualities of SAP. 
The interaction of SAP with several galactose-specific lectins 
including asialo-ceruloplasmin, bovine pneuma galactan, and several 
snail galactans has been reported (34). Interestingly, CRP and Clq 
also were shown to form precipitates in agarose when exposed to certain 
of these galactans. 
It has been demonstrated that SAP bound a non-T, non-B, acute 
lymphocytic leukemic (ALL) cell line as well as unseparated PBMe. Such 
binding of SAP was reduced in the presence of a snail galactan polymer 
(35). In these studies, it was shown that SAP suppressed the 
proliferation of PBMC and the non-T, non-B, ALL cell line in response 
to PPD and PHA. Similarly, the antibody 'production of PBMC after 
stimUlation with PWM was reduced in the presence of SAP. This 
suppression could only be observed when SAP was added within 24 hours 
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of initiation of culture. It was suggested that SAP may serve as an 
,endogenous lectin interacting with glycoproteins displaying exposed 
;' 
galactose residues either in plasma or on cell membranes. 
Investigation of the binding specificity of SAP for agarose, a 
linear galactan, was recently examined. It was demonstrated using an 
SAP-coupled Sepharose column that SAP had affinity for a synthetic 
'pyruvate acetal of galactose (36). This sugar is a natural trace 
contaminant of agarose. It was shown that pyruvate acetal of galactose 
,competitively inhibited the binding of SAP to Sepharose. Therefore, 
SAP may interact with certain sugar-bearing molecules in a lectin-like 
manner. 
II. The Clq sUbcomponent of the first component of complement. 
A. The biochemical characteristics of Clq. 
Clq is one of the three subcomponent molecules comprising the 
first component of complement which are held tegether in the presence 
of calcium (37). Clq is one of the most cationic proteins in human 
serum with gamma electrophoretic mobility_ The concentration of Clq in 
serum has been estimated to be 70-180 ug/ml (38). The molecular weight 
of Clq has been estimated as 410,000 (39). The carbohydrate content is 
approximately 8.3% (40). C1q is composed of six each of three chains 
A, B, and C (41). Each of these chains is approximately 200 amino 
acids with molecular weights of 27,000-34,800 (41). Each A chain forms 
a disulfide linked dimer with a B chain (42). The C chains form 
disulfide linked dimers with each other (42). 
The amino acid content of Clq subcomponent is very unusual for a 
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serum protein. It contains a high level of hydroxylysine and 
hydroxyproline (43). Furthermore, Clq contains a higher than normal 
level of glycine (42). This unusual amino acid and carbohydrate 
composition suggested that Clq was collagen-like. 
Collagen is composed of polypeptide chains containing the triplet 
Gly-X-Y where the X residue is often proline and the Y residue is often 
hydroxyproline or hydroxylysine (43). In the Clq molecule, each chain 
forms a minor helix and triplets of these polypeptide chains (A, B, C) 
together form a major helix. Six of these major helices associate with 
each other comprising the collagen-like fibril (44,45). 
By electron microscopic studies, Clq exhibits avery unusual 
structure. Six collagen-like strands are joined at one end to form a 
stem whereas at the other end the strands deviate forming a structure 
resembling an umbrella (46). Each collagen-like strand of the umbrella 
terminates in a non-collagen-like globular portion (46). At the 
point where the collagen-like fibrils diverge, the bend in the stem is 
somewhat flexible and acts as a hinge facilitating the enzymatic Clr 
and CIs SUbcomponents in their reactive functions (47). 
Interestingly, Clq has the ability to bind three bivalent calcium 
atoms per molecule (48). No function has been attributed to this 
calcium-binding. 
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B. Binding characteristics and the biological function of C1q. 
1. The interaction of Clq with Clr and else 
The majority of Clq in circulation is found in association with 
the other sUbcomponents of CI. Two molecules of Clr and two of CIs are 
associated with one molecule of Clq in the presence of calcium forming 
the 'reactive Cl molecule (48). The calcium requirement has been shown 
to be necessary for the dimerization of CIs and not for the interaction 
of Clr with Cls (48). Both Clr and CIs possess proteolytic 
activity and are virtually indistinguishable by amino acid sequence 
(49,50). When activated, both enzymes are serine proteases (51). The 
mechanism of activation of Clr is still unknown, but activated Clr 
results in proteolytic cleavage and activation of Cls (52). The 
mechanism for the Clr mediated activation of CIs has been explained by 
the structural conformation of the Cl molecule. By electron micrograph 
the Clr2C1s2 tetramer was shown to be made up of dimers of Clr with 
molecules of Cls at either end forming an "s" shaped linear chain (51). 
Dimers of Clr do not require calcium (53), but the presence of calcium 
allows the dimerization of the two terminally located Cls molecules 
forming a circular chain. This circle-shaped tetramer has been shown 
to form in a manner which incorporates the umbrella-like portion of Clq 
(54). When incorporated into the Clq molecule, Clr2C1s2 is maintained 
in a conformation which prevents activation. It has been suggested 
"" 
that when the angle of bend of the six strands of Clq is altered, for 
example, by interaction with immune complexes, the two Clr molecules 
become associated in a manner which allows auto-activation and 
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subsequent cleavage of the two CIs molecules. In this capacity, Clq 
bas been characterized as an allosteric effector for the activation of 
2. The interaction of Clq with Cl inhibitor. 
Cl inhibitor is an inhibitor of many serine proteases including 
Clr, CIs (56,57), plasmin (57), kallikrein (57,58,59), activated plasma 
thromboplastin antecedent (Xla) (60), and Hagemon Factor (XIIa) (60). 
In the case of CIr and CIs, one of these molecules forms a very stable 
complex with one molecule of Cl inhibitor (56,61). Calcium is not 
required for this reaction (62). Cl inhibitor preferentially inhibits 
activated CIs when in the pres·ence of noncomplexed activated Clr (63). 
Inhibition by Cl inhibitor is greatly enhanced by heparin (28,62,64, 
65). 
Recently, a role for CI inhibitor in control of activation of Cl 
has been postulated (66). The mechanism of control of CI activation by 
CI inhibitor was desc.ribed in the above investigation to be a result of 
the proximity of Cl inhibitor to Cl. The activation of Cl by specific 
activators such as immune complexes could not be inhibited by Cl 
inhibitor in the fluid phase, however, in the case of non-immune 
activators, inhibition was more efficient. 
3. The interaction of Clq with immunoglobulin. 
Each of the six globular heads of Clq has the ability to bind one 
immunoglobulin molecule (67). Activation of Cl requires binding of Cl 
by more than one immunoglobulin, i.e. aggregated by antigen, heat, or 
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other means. However, it has been demonstrated that Cl exhibits weak 
binding to monomeric immunoglobulin (68). The Fe regions of polymeric 
IgM, IgG3' IgGl, and IgG2 all show the ability to activate Cl with 
decreasing reactivity in the order listed (69). IgG4, 19A, IgD, and 
IgE all fail to bind Cl (39,69,70,71,72,73). 
4. The interaction of Clq with basement membrane. 
Several basement membrane constituents have been demonstrated to 
interact with Clq. The interaction of Clq with fibronectin has been 
well characterized. Fibronectin is a high molecular weight glyco-
protein found in plasma and in basement membrane associated with 
collagen (74). Fibronectin is the only connective tissue associated 
protein besides SAP which is also a normal plasma constituent (75). 
The interaction of fibronectin with Clq has been shown to occur with a 
higher level of binding to the collagen-like stem region than to the 
globular heads~ although significant binding to the globular heads was 
also demonstrated (76). 
Laminin~ another basement membrane component, has also been 
demonstrated to bind Clq (77). Laminin is a large glycoprotein which 
is found in basement membrane in association with type IV collagen 
(78). Thus, it appears there may be a family of proteins which bind 
Clq and alter its ability to interact with other reactive proteins. 
5. The interaction of Cl with bacteria and microorganisms. 
Cl has been shown to be activated by several bacterial species 
including Klebsiella, Salmonella, E. Coli (79-83)~ streptococcus (84), 
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and Staphylococcus (76). In addition~ Cl has been shown to be 
activated by mycoplasma (85)~ retroviruses (86-90), and parasites such 
as Schistosoma (91)~ and Trypanosoma (92). 
6. The interaction of Cl with other activators. 
Several proteins have been shown to activate Cl besides 
immunoglobulin. C-reactive protein, a homologue of SAP, has been shown 
to activate Cl (93,94), as has myelin basic protein (95,96). Certain 
carbohydrates (97,98)~ polyanions such as heparin (99,100,101), 
~ 
polynucleotides (102)~ and lipids (98,103) have been shown to activate 
C1. The large repertoire of molecules with which Cl interacts is 
indicative that there exists a family of reactive SUbstances which 
facilitate immunoregulation and immune clearance through nonspecific 
mechanisms. 
7. The C1q receptor. 
Many cell types exhibit the ability to bind free Clq. These 
include lymphocytes (104,105,106), B lymphocytes (107)~ monocytes 
(107), null cells (107), polymorphonuclear leukocytes (107), platelets 
(108,109), and endothelial cells (110). The binding of Clq to these 
cell surfaces was shown to be specific, reversible, saturable, and of 
moderately high affinity indicating that it is receptor mediated 
(104,107). The collagenous portion of Clq was shown to bind the 
receptor (lo4~107). Because native C1 was unable to bind the receptor, 
it was suggested that the binding site on Clq for the receptor was 
masked when complexed with Clr2C1s2. Thus~ binding of free Clq to such 
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receptor-bearing cells facilitates the interaction of Clq with its 
reactive ligands on the surface of immunoreactive cells. It seems 
likely that Clq is of great importance in regulation of the immune 
response at an early stage of activation. 
17 
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CHAPTER 2 
ROLE OF HUMAN SERUM AMYLOID P COMPONENT IN IMMUNE CLEARANCE 
THROUGH INTERACTIONS WITH Clq AND Fab~ 
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INTRODUCTION 
Serum amyloid P component (SAP) is a 9.5 S ~l-glycoprotein (1) 
found in plasma, amyloid deposits, and covalently linked to elastic 
fiber microfibrils in the connective tissue of glomerular basement 
membrane, skin, blood vessels, lung and gut (2,3). This 250,000 dalton 
glycoprotein is made up of ten identical 23,500 dalton subunits 
non-covalently linked to form two face-to-face pentagonal structures 
(4). The similarity in structure between SAP, C-reactive protein (CRP) , 
and hamster female protein (HFP) has led to the classification of these 
pentameric proteins as pentraxins (4,5). In humans, SAP, unlike CRP, is 
not an acute phase reactant (6). SAP has been found in all vertebrate 
species studied, and SAP has never been found to be deficient in any 
individual (7). Because of the evolutionary conservation of the 
biochemical properties of SAP, the role of SAP is assumed to be of 
importance. While no biological function for SAP has thus far been 
reported, SAP has been speculated to interact with or be involved with 
fibronectin, c4 binding protein (8), platelet activation (9), 
inflammation (10), complement (11,12), and coagulation (13). The 
specific role that SAP plays in the above systems is not understood. 
SAP was, at one time, named CIt, a presumed fourth subcomponent of 
the C1 molecule (14). These authors found that SAP was co-purified with 
Cl when serum was passed through a Sepharose-IgG column. Later, it was 
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discovered that SAP had a calcium-dependent affinity for Sepharose 
(15), and Cooper and Ziccardi (16) showed by a series of comparisons 
that SAP neither functionally nor physically interacted with the C1 
molecule. In the latter work, the inability of SAP to interact with C1 
was examined by sucrose density gradient ultracentrifugation, CH50 
assay, and Cl hemolytic assay. It is noteworthy that the latter two 
experiments were performed in the presence of gelatin. The reported 
variable effects of SAP on complement hemolytic activity (16) suggested 
to us that gelatin might be interfering with the SAP-C1 interaction 
(i.e. when C1 is in the fluid-phase as opposed to the EA-bound phase). 
Cooper and Ziccardi (16) also reported that SAP did not associate with 
C1 in sucrose density gradient ultracentrifugation, however, the calcium 
concentration (O.15 mM) in the gradient was 1/10 physiological level 
which may have adversely affected the ability of SAP to interact with 
C1. Furthermore, the relative effect of sucrose on SAP binding was not 
compared with other density gradient media. 
In a similar study (14), when serum was examined for the 
association of SAP with C1 by ultracentrifugation, it was found that in 
a Ficoll gradient, SAP appeared to be associated with C1, whereas use of 
a sucrose gradient gave variable results. Furthermore, in the above 
study, the association of SAP with C1 was demonstrated in a gradient 
containing 1 mM calcium, whereas in the presence of EDTA no association 
of SAP with C1 could be demonstrated. 
It was shown earlier by Cooper and Ziccardi (16) that SAP might 
have a calcium-dependent affinity for IgG. It seemed possible, 
therefore, that SAP could affect the interaction of aggregated IgG with 
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complement. Results presented here are consistent with the postulation 
that SAP interacts with both C1q and with the Fab region of aggregated 
IgG. 
MATERIALS AND METHODS 
Isolation of human SAP: 
Serum amyloid P component was prepared as previously described by 
Anderson and Mole (17). Basically, air-contaminated plasma was obtained 
from the American Red Cross and delipidated by centrifugation for three 
hours at 2000 g. This clarified plasma was precipitated by addition of 
15 gIl barium chloride, and the precipitate was washed and resolubilized 
in 0.15M sodium citrate, pH 1.6. The resulting solution was 
precipitated with ammonium sulfate, and the fraction precipitating 
between 30% and 60% was collected and resolubilized in O.OlM phosphate 
buffer, pH 7.2, dialyzed against the same buffer, and chromatographed on 
a 2x15 cm DE-52 ion exchange column. A 500 ml gradient from O.OM - O.7M 
NaCl in phosphate buffer was applied, and the fraction containing SAP 
eluted at approximately a.2M NaCl. SAP was quantitatively detected 
using rocket ~unoelectrophoresis or by measuring the absorbence using 
the extinction coefficient E1% = 18.2 at 280 nm (18). Goat antiserum to 
1cm 
P component (SAP) was obtained from Atlantic Antibodies, Scarborough, 
MA. 
SAP was further purified using affinity chromatography on Sepharose 
4B in a.1M TRIS, 0.15M NaCl, 5mM CaCl2. SAP was subsequently eluted by 
application of O.lM TRIS, 0.15M NaCl (without CaCl2). The eluted 
protein was concentrated with polyethylene glycol and dialyzed against 
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O.005M Na-5,5' diethyl barbituate, 0.15M NaCl, pH 7.4 (VBS). The 
veronal buffered saline did not contain gelatin. 
The SAP preparation was examined for purity using PAGE in a 9~ gel, 
and only one high molecular weight band was detected at approximately 
200,000 daltons when 10-50 ug purified SAP was applied to the gel in 
the absence of SDS. When this SAP preparation was examined in 
the presence of SDS, only one low molecular weight band appeared at 
23,000 daltons. Only one band was apparent in PAGE. There was only 
one precipitin arc in the SAP preparation when crossed IEP was 
performed against antiserum to whole human serum. 
Isolation of human Clq: 
C1q was isolated as described by Yonemasu and Stroud (19) and 
dialyzed against VBS. Isolated C1q was quantitated using the extinction 
coefficient E1% = 6.82 at 280 nm (20). In a 5%-30% gradient SDS-PAGE, 
lcm 
... there was one band in the Clq preparation at 410,000 daltons when 10-25 
ug purified Clq was applied to the gel. 
Iodination of SAP and Clq: 
Clq and SAP were radiolabelled with 125INa utilizing 30 ul 
chloramine T (1 mg/ml) at a concentration of 1 mCi/34 ug Clq or 1mCi/40 
ug SAP in 250 ul VBS. The reaction was stopped by addition of 30 ul 
Na-metabisulfite (2 mg/ml). Radiolabelled Clq and SAP were separated 
from free 1251 by gel filtration on a G-50 column. 
39 
Immunoglobulin and immunoglobulin fragments: 
IgG, FC~, and Fab~(Chrompure proteins) were obtained from Jackson 
Immunoresearch Labs Inc., Avondale, PA. Aggregation of IgG was achieved 
by heating at 63°C for 30 min. All preparations were diluted to defined 
concentrations in VBS. 
C3 conversion in crossed immunoelectrophoresis (IEP): 
Activation of serum complement C3 was determined by measuring the 
proportion of cleaved C3 using crossed IEP against antiserum to C3 
(21). Antiserum to C3 was obtained from Atlantic Antibodies, 
Scarboruogh, MA. Serum at a final concentration of 1:3 was incubated-
for 60 min at 37°C in VBS with a final concentration of 1.5mM CaC12' ImM 
MgS04 in the presence or absence of activators before electrophoresis 
was performed. 
Affinity chromatography of 125I-C1q to SAP on Sepharose 4B: 
A 3 ml column of Sepharose 4B was prepared by incubating the beads 
overnight at 4°c in the presence of 2% BSA in VBS. This column was 
equilibrated in VBS containing 5mM CaC12. Each sample applied to the 
column contained 8 ul 125I-Clq (34 ug/ml), and 10 ul of either VBS, SAP 
(155 ug/ml in VBS) , or 5% BSA with a final concentration of 5 mM CaC12. 
All samples were incubated for 10 min. at 37°C and diluted to 250 ul in 
VBS containing 5 mM CaC12 before application to the column. Fractions 
were collected in 1 ml volumes with a flow rate of 6 ml/hour. 1 25I-Clq 
in presence of BSA was used to represent maximum 125I-Clq. Percent 
binding was calculated as follows: 
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1 -
Sum of fraction cpm in presence of SAP 
Sum of fraction cpm in presence of BSA X 100 
Pepsin digestion of Clq molecule: 
Digestion of Clq with pepsin (Sigma) followed the procedure described by 
Reid (22). Briefly, pepsin was incubated with Clq at a 1:30 ratio for 
20 hours at 37°C. The collagen-like fragments of the Clq molecule were 
separated from the remaining proteins by gel filtration on a 1x30 em 
G-200 column. Fractions containing the collagen-like portion were 
lyophilized and reconstituted in VBS. 
SAP crossed IEP: 
Interaction of SAP with various proteins (e.g. Clq) was determined 
by crossed IEP against 0.67% goat antiserum to SAP. In these stUdies 
SAP was incubated with the test sUbstance for 10 min. at 37°C in VBS 
which contained 1.5 mM calcium (VBS++) before crossed IEP. Note that 
the concentration of Ca++ is at near phyiological level and is ten times 
higher than the level used in standard complement buffers. 
Microtitre solid phase binding assay: 
Polystyrene microwells (Removastrips, Dynatec Lab., Alexandria, 
Va.) were utilized to examine the binding of 125I-SAP to various test 
proteins by a method previously described (23). Briefly, 300 ul of the 
test protein at various concentrations in VBS was incubated in the 
microwells for 60 min. at room temperature. After washing once with 
VBS, the microwells were blocked with 300 ul 1% BSA in VBS for 30 min. 
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at room temperature. Wells were washed once with VBS, and 300 ul 
125I-SAP at 17-33 ng/ml in VBS++ was allowed to incubate in the wells 
overnight at 4°c. Control wells without test protein consisted of VBS 
buffer only (maximum) and 1% BSA only (background). These control wells 
were used to calculate maximum and minimum binding of 125I-SAP. Percent 
binding was calculated as follows: 
(cpm in test well) - (cpm in BSA well) X 100 
(cpm in buffer well) - (cpm in BSA well) 
RESULTS 
Interaction with Clq: 
When SAP was first incubated with various concentrations of Cl 
(Cordis) for 10 min at 37°C in VBS++, there was a loss of detectable 
SAP, as determined by subsequent crossed IEP against antiserum to SAP. 
In order to d,etermine whether SAP interacted with the Clq SUbcomponent 
of Cl several approaches were used. 
Various concentrations of Clq in VBS++ were incubated with a 
constant amount of SAP for 10 min. at 37°C and mixtures were examined 
for SAP migration utilizing crossed IEP. A loss of precipitable SAP was 
observed when using a ratio of 67 ug Clq: 40 ug SAP (Fig. 1). A 1.0 to 
2.5 mM concentration of Ca++ was required for the above interaction. 
Addition of 0.04 M EDTA completely blocked the interaction. 
A second method for studying the interaction of SAP with C1q 
utilized the affinity of SAP for agarose (15). In these studies, the 
role of SAP in mediating the binding of radiolabelled 125I-Clq was 
measured. 125I-Clq (15.1 ug/ml) was first incubated with SAP (86.1 
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ug/ml) in VBS++ for 10 1 at 37°C, then the mixtures were applied to a 3 
ml Sepharose 4B column in VBS containing 5 mM Ca++. 70% of the 125I-Clq 
was retained (Fig. 2). When CaCl2 was subsequently removed from the 
column by washing with VBS minus calcium, 71% of the bound 125I-Clq was 
recovered (Table 1). 125I-Clq alone was applied to Sepharose 4B in 
VBS++. In these controls less than 1% of 125I-Clq was retained. 
Interaction of SAP with the collagen-like regions of Clq: 
Because of the similarities between the stem region of Clq and 
collagen, the interaction of SAP with collagen was examined. For these 
studies a microtitre solid-phase binding assay was used. 125I-SAP was 
shown to interact with both type I collagen (Collagen Corp., Calif.) and 
type IV collagen (kindly donated by Dr. Gary Grotendorst, Department of 
Rheumatology/Immunology, MUSC) in a dose dependent manner (Fig. 3). The 
degree of binding of SAP with type IV collagen was 2.7 times higher than 
with type I collagen. Both interactions were optimized by using a 
concentration of 30-40 ug/ml collagen with 17-33 ng 125I-SAP. 
Furthermore, 125I-SAP interacted with gelatin at levels similar to its 
interaction with type IV collagen (data not shown). 
In order to directly determine whether SAP might interact with the 
collagen-like stem of Clq, Clq was digested with pepsin, and the stem 
was isolated from the protease and remainder peptides. 125I-SAP bound 
to the Clq stem region as determined by the solid phase microtitre assay 
(Fig. 4). 
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Interaction of SAP with IgG and Fab~: 
SAP (40 ug/ml) was incubated with purified IgG (50-100 ug/ml) for 
10 min at 37°C. By crossed IEP against antiserum to SAP, it appeared 
that SAP interacted with IgG when calcium (1.5 mM) was present. In 
other words, the SAP immune precipitates observed in the second 
direction of crossed IEP diminished in the presence of IgG and this 
effect was Ca++ dependent. 
In addition, a microtitre solid-phase binding assay was utilized in 
order to further investigate the interaction of SAP with IgG. The 
binding of 125I-SAP to ~obilized IgG occurred in a dose dependent 
manner. The most efficient binding of 125I-SAP occurred when the 
microwells were coated with 20 ug/ml IgG followed by 125I-SAP at a 
concentration of 33 ng/ml (Fig. 5). The interaction of immobilized IgG 
with 125I-SAP was shown to occur in the presence of calcium. In the 
absence of calcium, no binding' of l25I-SAP to IgG was observed. 
When the pepsin fragments of IgG were examined by the same type of 
solid-phase binding assay it was found that 125I-SAP interacted with the 
Fab~- portion in a dose dependent manner (Fig. 6). However, no binding 
of SAP to the Fc~ portion was detected (Fig. 7). 
In order to examine the effect of SAP on the interaction of Clq 
with immunoglobulin and vice versa, 125I-SAP was first complexed to Clq 
and then tested for binding to immobilized IgG or to its Fab~' and FC~ 
fragments. A mixture with a final concentration of 44 ng/ml Clq to 
33 ng/ml 125I-SAP in VBS++ was incubated 10 min. at 37°C. This 
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mixture was allowed to incubate in the microwells which had previously 
been coated with either IgG (33 ng/ml), Fab,... (66 ng/ml), or Fcc( (66 
ng/ml) and washed. It was found that when 125I-SAP was first complexed 
with Clq the binding of 125I-SAP-Clq complexes to IgG or Fab~ was 24% as 
compared to free 125I-SAP (not pre-mixed with Clq) (Table 2). Further-
more, when 125I-SAP was first complexed with Clq there was no increase 
in binding to 125I-SAP to Fc~/as compared to free 125I-SAP. 
In a similar set of experiments, 125I-SAP was first complexed with 
either IgG or Fab~and then tested for binding to immobilized Clq. A 
mixture with a· final concentration of 33 ng/ml IgG to 33 ng/ml 
125I-SAP in'VBS++ was incubated 10 min. at 37°C. This mixture was 
allowed to incubate in the microwells which had previously been coated 
with Clq (133 ng/ml). In this experiment, when 125I-SAP was first 
complexed with IgG, 73.7% of the 125I-SAP bound to immobilized Clq as 
compared to free 125I-SAP (without IgG). Complexes of Fab~ (66 ng/ml) 
and 125I-SAP (33 ng/ml) showed 38.1% 125I-SAP bound to immobilized Clq 
as compared to free 125I-SAP. 
Activation of the complement pathway by SAP: 
An individual has been previously characterized with a reduced 
level of Cl inhibitor (24). When SAP was incubated for 1 hr at 37°C 
with this sera, SAP activated complement as determined by C3 conversion. 
Approximately 50% less C3 conversion was observed when SAP was incubated 
with normal sera. The C3 conversion caused by isolated SAP (0.12 mg/ml) 
in the Cl inhibitor deficient serum was comparable to the C3 conversion 
caused'by 0.5 mg/ml heat-aggregated IgG in the same serum (Fig. 8). As 
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expected, when exogenous Cl inhibitor was added before the incubation of 
SAP with Cl inhibitor deficient serum, the activation of complement by 
SAP was restricted (Fig. 9). These results support the concept that 
the activation of the complement pathway by the isolated SAP might be 
through the interaction of SAP with the Cl molecule. 
DISCUSSION 
There has been some controversy about the association of SAP with 
Cl. Originally, SAP was reported to be a sUbcomponent of Cl (14), but 
later, it was reported that SAP and Cl had no functional or physical 
interaction (16). In this study, the ability of SAP to interact with Cl 
was re-examined. 
The binding of Clq-SAP mixtures were studied using affinity 
chromatography. In this system, the ability of SAP to bind agarose 
(Sepharose 4B) in the presence of calcium was utilized. When 125I-Clq 
was first pre-incubated with SAP, 70% or greater of the 125I-Clq was 
retained by the Sepharose. Furthermore, when the calcium was cleared 
from the column, 71% of the bound 125I-Clq was recovered. In control 
studies it was shown that 125I-Clq (without SAP, but with BSA) was not 
significantly retained by Sepharose 4B. These experiments indicated 
that SAP was probably interacting with Clq and mediating the Clq binding 
to the agarose. 
In order to further sUbstantiate the interaction of SAP with Clq, 
SAP crossed IEP was performed. In these experiments, various 
concen~rations of Clq or intact Cl were pre-incubated with a constant 
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amount of SAP prior to electrophoresis. It was observed that there was 
a loss of precipitable SAP as compared to controls without Cl or Clq. 
Furthermore, the greatest loss of detectable SAP occurred with 
approximately equimolar ratios of SAP to Clq and in the presence of 
calcium. 
SAP crossed IEP on agarose has properties which can be used to 
detect binding of SAP to Clq. For example, SAP interacts with agarose 
but only in the presence of calcium. In addition, Clq has a gamma 
mobility, and this limits the ability of SAP when complexed with Clq to 
migrate in a crossed IEP system at pH 8.6-8.8. Indeed, complexes of SAP 
with Clq did not migrate into the antiserum-containing agarose. Thus-, 
the lack of precipitate formation in the second direction of SAP crossed 
IEP was used as an indirect measure of binding of SAP to Clq. 
The Clq molecule is composed of a collagen-like stem, six strands 
of which form an umbrella-like structure and terminate in proteinacious 
globular heads (25). The globular heads of Clq have an affinity for the 
Fc portion of the immunoglobulin molecule (26). To examine the 
interaction of SAP with the collagen-like stem of Clq, the ability of 
SAP to interact with the pepsin digest of Clq was investigated. In a 
microtitre solid phase binding assay, it was observed that binding of 
125I-SAP to the immobilized Clq stem fragments occurred in a dose 
dependent manner in the presence of calcium. Therefore, SAP probably 
interacts with the stem of Clq, unlike IgG which interacts with the 
globular heads. 
In further examining whether SAP might interact with the collagen-
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like stem, the ability of SAP to interact with collagen types I and IV 
was comparatively investigated. Using a microtitre solid-phase binding 
assay, it was shown that 125I-SAP interacted with collagen types I and 
IV in a calcium dependent manner. The interaction of SAP with type IV 
collagen was 2.7 times higher than with type I collagen. Furthermore, 
in the same type of assays, 125I-SAP interacted with gelatin at levels 
similar to its interaction with type IV collagen. 
Collagen type IV is located in epithelial and endothelial basement 
membranes (27). Neither fibers nor fibrils are detectable, rather 
microfibrils appear to be randomly distributed forming a felt-like 
matrix (28,29). It has been reported that SAP (amyloid P component) 
binds covalently to elastic fiber microfibrils in basement membranes and 
that SAP is released by collagenase (2,3). Based on the finding that 
SAP shows a calcium dependent binding to type IV collagen, it is likely 
that SAP is located on collagen microfibrils in basement membranes. 
Tissue injury resulting from physical trauma or from infection by 
microorganisms initiates a series of events involving complement which 
increase vascular permeability. One of the tissue SUbstances to which 
serous fluids are exposed during this process is SAP (amyloid P 
component) which is immobilized on basement membranes. At a site of 
trauma, the interaction of tissue-bound SAP with serum Clq may allow SAP 
to interact with the complement pathway. 
It is possible that SAP, either in circulation or in tissue, binds 
to SUbstances on the surfaces of microorganisms (e.g. zymosan, 30), and 
when aggregated may facilitate complement activation via the classical 
pathway. 
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The interaction of SAP with gelatin suggested that gelatin would 
interfere with experimental testing of the interaction of SAP with other 
proteins in assays which contain gelatin. Gelatin is often a component 
of buffers used in complement hemolytic assays. Since we determined 
that gelatin binds SAP, it is possible that gelatin may influence the 
interaction of SAP with complement. 
In a separate set of experiments, the ability of SAP to interact 
with IgG, Fab~, and Fc~, was studied utilizing the microtitre solid-
phase binding assay. These experiments established that SAP interacted 
with Fabyand did not interact with F~. The interaction of SAP with 
IgG has been suggested previously (16), however, studies on the 
interaction of SAP with IgG fragments have not been reported. 
In primary amyloidosis, the amyloid fibrils are composed of A-
chains. In these, and other types of amyloid deposits, the SAP molecule 
is found bound to the fibrillar portion of the deposits in a calcium 
dependent manner (31). We determined that SAP has a calcium dependent 
affinity for Fab~ using our solid-phase binding assay. Therefore it is 
conceivable that SAP interacts with the light chain of the Fab~region. 
Such a function may be related to the deposition of SAP and of ~- chains 
as observed in amyloid deposits. 
A series of microtitre solid-phase binding assays were performed to 
study the ability of SAP, IgG, and Clq to interact concomitantly. In 
these studies, 125I-SAP, with or without pre-incubation with IgG or IgG 
fragments was examined for binding to immobilized Clq. After 
pre-incubation of 125I-SAP with IgG, the binding of 125I-SAP to 
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immobilized Clq was 26% lower than free 125I-SAP (without IgG). 
However~ when 125I-SAP was pre-incubated with Fab~, the binding of 
125I-SAP to immobilized Clq was 62% lower than free 125I-SAP (without 
Fab~). This indicated that Fab~ probably blocked the binding site on 
SAP for Clq. Furthermore, the fact that there was a greater loss of 
125I-SAP binding to Clq when 125I-SAP was pre-incubated with Fab7 than 
with intact IgG can be explained by the lack of the Fe region which is 
known to bind to Clq. 
In other studies, 125I-SAP, with or without pre-incubation with 
Clq, was examined for binding to immobilized IgG or Fab~. When 125I-SAP 
was first pre-incubated with Clq, the binding of 125I-SAP to both IgG .. 
and Fab~ was 76% lower than free 125I-SAP (without Clq). The presence 
or absence of Fc region did not make a significant difference in the 
percent inhibition. If SAP binds to the Clq stem region proximate to 
the globular heads, then SAP may restrict the Clq globular heads from 
properly interacting with FC~. Such an effect would neutralize the 
Clq-Fc interaction. 
Since SAP was found to interact with Clq, it was of interest to 
determine the ability of SAP to influence the activation of complement. 
When SAP was incubated with serum containing decreased levels of Cl 
inhibitor, C3 conversion occurred. It was demonstrated that the 
activation of complement by SAP in Cl inhibitor deficient serum was 
restricted by addition of exogenous Cl-inhibitor giving further evidence 
that isolated SAP may interact with the classical complement pathway. 
In summary, we suggest that SAP interacts with Clq in a calcium-
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dependent manner. Because SAP also interacts with collagen types I and 
IV, we speculate that the interaction of SAP with Clq is through the 
collagen-like region. This postulation was supported by the binding of 
SAP to the residual fragments after pepsin digestion of the Clq 
molecule. We have also demonstrated that SAP interacts with Fab~. The 
ability of SAP to activate the complement pathway in Cl inhibitor 
deficient serum is restricted in the presence of sufficient levels of 
exogenous Cl inhibitor. In areas where Cl inhibitor is depleted, i.e. 
by binding to activated Hageman Factor, kallikrein, or plasmin (32,33) 
SAP mediated effects on Cl activation may be enhanced. 
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Table 1. Retention of 125I-Clq by SAP on Sepharose 4B 
SAMPLE APPLIED 125I-Clq NOT RETAINED 125I-Clq ELUTED 
CPM Percent CPM Percent 
125I_C1q + BSA 219873.0 96.4 8110 3.6 
+ 168.2 + 1068.8 - -
\ 
125I-Clq + SAP 69204.0 31.5a 107382.3 71.3b 
:. 1177.6 + 1144.1 -
a) For calculations, 125I-Clq + BSA vas used to represent maximum 125I-Clq in 
unbound fractions. 
b) For this calulation, 125Clq + SAP retained (difference betveen 125I-Clq in 
presence of BSA and SAP) was used to represent maximum in bo~nd fraction. 
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Table 2. INTERACTION OF 125I-SAP WITH Clq AND IgG CONCOMITANTLY 
Well-coat Samplea Percent Bindingb 
IgG l25I-SAP + VBS 100 
(10 mg!ml) l25I-SAP + Clq 24 
Fab-.r 125I-SAP + VBS 100 
(20 mg/mJ..) 125I-SAP + Clq 24 
"125I-SAP + VBS 100 
Clq 125I-SAP + IgG 74 
(40 mg/ml) 125I-SAP + Faby- 38 
a) For these experiments, 10 ul of 125I-SAP (10ug/ml) and 10 ~l of the test 
sUbstaoce (as described) vere added to the pre-coated microtitre vells 
containing 280 ul VBS, 1.5 mM calcium, and incubated overnight at 4°C. 
b) For calculations, 125I-SAP + VBS alone vas used to represent maximum 
binding. 
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Fig. 1 SAP crossed immunoelectrophoresis demonstrating diminishing 
SAP precipitates in the presence of increasing concentrations 
of Clq. 1) SAP + VBS; 2) SAP + C1q (67 ug/ml); 3) SAP + C1q 
(34.6 ug/ml); 4) SAP + C1q (17.3 ug/ml); 5) SAP + Clq (8.7 
ug/ml). A constant amount of purified SAP (40 ug/ml) was 
incubated with decreasing concentrations of purified C1q in 
VBS++ for 10 min. at 37°C prior to electrophoresis. Agarose 
in the second direction contained antiserum to SAP. Anode is 
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Fig. 2 Sepharose 4B affinity chromatography profiles of 125I-C1Q with 
or without SAP. 125I-C1Q was incubated with VBS (. -), 5% BSA 
(_ .), or SAP (. .) for 10 min. at 370C in VBS, 5 mM calcium. 
Each sample was passed through a Sepharose 4B column and the 
unbound fractions collected. Bound fractions were collected by 
removing calcium. Each fraction represents 1 ml. 
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Fig. 3. Dose-response curves of binding of 125I-SAP in VBS++ to 
immoblized collagen, types I and IV. Wells in a polystyrene 
microtitre solid-phase binding assay were pre-coated with 
various dilutions of collagen, type I ( ) or type IV 
( •••• ). After blocking with 1% BSA, a constant amount of 
125I-SAP(5-10 ng/ml) in VBS++ was allowed to incubate in the 
wells overnight at 4°c. The contents of the wells were 
aspirated, washed, and counted. 
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Fig. 4. Dose-response curves of binding of 125I-SAP to immobilized .. 
Clq stem region. Wells in a polystyrene microtitre solid-
phase binding assay were pre-coated with various dilutions of 
Clq stem region. After blocking with 1% BSA, a constant 
amount of 125I-SAP(5-10 ug/ml) in VBS++ was allowed to 
incubate in the wells overnight at 4°c. The contents of the 









Fig. 5. Dose-response curves of binding of 125I-SAP to immobilized.· 
IgG. Wells in a microtitre sOlid-phase binding assay were 
pre-coated with various dilutions of IgG. After blocking 
with 1% BSA, a constant amount of 125I-SAP (5-10 ug/ml) in 
VBS++ was allowed to incubate in the wells overnight at 4°C• 

























Fig. 6. Dose-response1curves of binding of 125I-SAP in VBS++ to 
immobilized Fab~. Wells in a polystyrene microtitre solid-
phase binding assay were pre-coated with various dilutions of 
Fab. After blocking with 1% BSA, a constant amount of 
125I-SAP (5-10' ug/ml) in VBS++ was allowed to incubate in the 
wells overnight at 4°c. The contents of the wells were 





































Fig. 7. Dose-response curves of binding of 125I-SAP in VBS++ to 
immobilized Fc7 • Wells in a polystyrene microtitre solid-
phase binding assay were pre-coated with various dilutions of 
Fe. After blo~ing with 1% BSA, a constant amount of 
125I-SAP (5-10~ ug/ml) in VBS++ was allowed to incubate in the 
wells overnight at 4°c. The contents of the wells were 
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Complement activation as measured by C3 conversion in normal 
human sera ( 111111 ) and se~ from an individual with decreased 
levels of Cl inhibitor ( Q58 ). Percent conversion was 
calculated as that fraction of total C3 which was converted. 
Converted C3 was estimated as the area of the converted 
precipitate, and total C3 was estimated as the sum of the 
areas of the precipitates representing native and converted 
C3. Ey student's t-test, the C3 conversion in normal sera 
was significantly less than in serum with decreased levels of 
Cl inhibitor when complement activation was caused by 
heat-aggregted IgG (t5 = 3.46; p~O.Ol) and by SAP (t5 = 6.56; 
p~O.OOl). There was no significant difference in spontaneous 
C3 conversion between normal sera and serum with decreased 

























Fig. 9 • C3 conversion immunoelectrophoresis of serum from an 
individual with decreased levels of Cl inhibitor. 1) serum + 
VBS; 2) serum + heat-aggregated IgG (0.5 mg/ml); 3) serum + 
exogenous C1 inhibitor (37.5 mg/ml); 4) serum + SAP (0.12 
mg/ml); 5) serum + exogenous Cl inhibitor (37.5 mg/ml) + SAP 
(0.12 mg/ml). Final serum concentration was 1:3. Incubation 
of serum with activators and/or inhibitors for 6~ min. at 
370C was carried out in the presence of 1.5mM Ca + and 1mM 
Mg++. Agarose in the second direction contained antiserum to 









Serum amyloid P component (SAP) is a high molecular weight plasma 
glycoprotein also found in basement membrane (1). This glycoprotein 
was first identified as a component of amyloid deposits bound to 
, 
amyloid fibrils (2). Later, SAP was named CIt, a fourth subcomponent 
of the first complement component (3). Further evidence indicated that 
the purported CIt was, in fact, SAP (4), and that SAP was not a 
subcomponent of CI (5). 
By examining the electrophoretic patterns of SAP by crossed rEP"; 
I observed a loss of precipitable SAP is in the presence of CI or Clq 
when compared to SAP alone. This indicated that in the presence of Cl 
or Clq there was no interaction between SAP and anti-SAP in the second 
direction of IEP. The interaction of SAP with Cl and Clq was calcium 
dependent, and in the presence of EDTA, the interaction was abolished. 
In a second method for demonstrating the interaction of SAP with Clq, I 
utilized the ability of SAP to mediate the binding of I25I-CIq to 
Sepharose 4B. When 125I-C1q was first incubated with SAP in the 
presence of calcium, greater than 70% of the 125I-Clq was retained by 
the column. When the calcium was subsequently washed from the column, 
71% of the bound 125I-Clq was recovered. In control studies, I25I-Clq 
was not retained by Sepharose 4B in the absence of SAP indicating that 
I25I-Clq remained in the Sepharose column as a hitchiker on the SAP 
molecule. 
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The Clq molecule has a collagen-like region and six proteinacious 
globular heads. The globular heads interact with the Fc region of 
immunoglobulin. Evidence indicates that the collagen-like stem may 
interact with fibronectin (6) and laminin (7), both basement membrane 
constituents. In further investigating the interaction of SAP with 
Clq, I found that SAP, also a basement membrane constituent, interacted 
with the collagen-like stem of Clq and with collagen, types I and IV, 
in a calcium-dependent manner. This is interesting, first of all, 
because it indicates that SAP may be associated with collagen in 
basement membrane. Secondly, the affinity of the Clq stem for several 
basement membrane constituents indicates there may exist a family of 
molecules in damaged tissue involved in immune clearance, localization 
of reactive substances, and regulation of the inflammatory response. 
By using a solid phase microtitre binding assay I found that SAP 
had a calcium-dependent affinity for IgG. The interaction of SAP 
itself with immunoglobulin highlights the possibility that SAP is 
directly involved in regulation of the inflammatory response. Of 
considerable interest is the ability of SAP to interact with the Fab 
portion of IgG in a calcium-dependent manner. No other molecule has 
been reported to interact with IgG in such a manner. Furthermore, I 
found that SAP bound Clq and IgG concomitantly. When SAP was coupled 
to the Fab of intact IgG via calcium, SAP retained the ability to bind 
Clq, which in turn retained its ability to bind the Fc region of IgG. 
Conversely, when SAP was coupled to Clq via calcium, SAP lost the 
ability to interact with either IgG or Fab~ These facts indicate that 
in damaged tissue, SAP exposed to serous fluids may bind IgG or Clq 
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depending on the concentrations present. Regulation of the functional 
capacity of Clq or IgG would be modulated by SAP in such cases. 
Because SAP has affinity for Clq, I investigated the ability of 
SAP to activate complement. Interestingly, SAP itself possessed the 
ability to activate complement. Activation caused by SAP in the 
•• 
~ 
fluid-phase was restricted in the presence of Cl inhibitor as opposed 
to activation caused by specific activators such as heat-aggregated 
IgG. This indicated SAP probably interacted with Cl and caused 
activation of the classical pathway. Therefore, in damaged tissue 
sites where Cl inhibitor has been depleted, SAP may activate Cl on the 
basement membrane surface providing a mechanism for localization of ._ 
complement activators in tissue as opposed to activation in the 
fluid-phase. 
SAP has been identified in amyloid deposits bound to the fibillar 
component (2). The fibrillar component has been identified as being one 
of several normal plasma constituents or fragments thereof including 
primarily ~ -chain (8) or serum amyloid A component (2). Serum amyloid 
A component is an acute phase reactant which has no known function. 
The deposition of A chains, A-chain fragments, and serum amyloid A 
component in amyloidosis probably occur as a result of defective 
clearance mechanisms. The identification of SAP on such fibrillar 
deposits indicates SAP may be involved in the process of immune 
clearance. 
In summary, the ability of SAP to interact with Cl and, 
specifically, Clq indicates that SAP may mediate an important role in 
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modulation of the complement pathway. The ability of SAP to interact 
with Fab~ indicates SAP may mediate an important role in modulation of 
immune complex formation and activity. Furthermore, the ability of SAP 
to interact with Clq and IgG concomitantly indicates SAP may mediate 
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